Viewing Study NCT00441922



Ignite Creation Date: 2024-05-05 @ 5:23 PM
Last Modification Date: 2024-10-26 @ 9:31 AM
Study NCT ID: NCT00441922
Status: COMPLETED
Last Update Posted: 2008-10-29
First Post: 2007-02-28

Brief Title: Trial of Docetaxel Versus Vinorelbine as 1st Line Treatment in Elderly Patients With Non-Small-Cell Lung Cancer NSCLC
Sponsor: Hellenic Oncology Research Group
Organization: Hellenic Oncology Research Group

Study Overview

Official Title: A Multicenter Randomized Phase II Study of Docetaxel Versus Vinorelbine as First-Line Treatment in Elderly Patients With Advanced Non-Small-Cell Lung Cancer NSCLC
Status: COMPLETED
Status Verified Date: 2008-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This trial will compare the efficacy of docetaxel versus vinorelbine as first-line treatment in elderly patients with advanced NSCLC
Detailed Description: Docetaxel and vinorelbine are well known active agents in the treatment of NSCLC The standard treatment of elderly patients with advanced NSCLC is monotherapy with a third generation agent The role of comprehensive geriatric assessment in treatment efficacy and tolerance is an area of investigation

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None